If you can't see this email correctly, click here.
avance logo top image
News in Avance Your Source for Valuation header 3

Why drug prices must be high:

It's not because of large R&D expenditures

Drugs are expensive compared to their cost of goods, and pharmaceutical companies are far more profitable than leaders in other industries. Pharma typically justifies the prices with high R&D expenditures. The truth is more complex with farther-ranging implications.



16/06/2010 and 18/06/2010
Negotiation and Legal Terms of License Contracts

Valuation Book

Valuation in Life Sciences
Become a valuation expert yourself. "Valuation in Life Sciences. A Practical Guide" has become the industry reference book and is currently in its second edition.

Click here to order.

ri:val: What deals do your peers negotiate?
Avance regularly analyses industry deals with respect to their composition, structure and terms. From most deals only fragments are disclosed such as the sum of milestones and whether the royalties are single- or double-digit. With the help of ri:val we shed more light on these deals.

This example is a phase 2 cancer deal between Pfizer and Celldex.


 ri:val >

Negotiation and Legal Terms of License Contracts:
3-day workshop in Davos

Due to the large interest Avance holds again a 3-day workshop on negotiation, legal clauses, and valuation of term sheets. Together with Monika Naef and René Muttenzer, two renowned industry lawyers in pharma, we will equip the participants with the theoretical foundation and anecdotes to work in groupson an intensive case study.


You can sign up for News in Avance or change your e-mail address here.
Copyright: Avance, Basel GmbH - Bäumleingasse 2 - CH - 4051 Basel